head and neck cancer
Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Premium
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
The firm is aiming to commercialize its OncoPrism assay in 2023 as a laboratory-developed test to identify head and neck cancer patients eligible for checkpoint inhibitors.
Naveris Nabs $33.4M Series A Round Expansion to Further Commercialize Virus-Related Cancer Tests
The new funding brings the total investment in the firm to $51 million, which Naveris will use for commercialization of its NavDx assay.
Immune Checkpoint Blockade Response Linked to Recurrent Mutations in Genes, Pathways
Exome sequences for hundreds of cancer patients led researchers to four recurrently mutated genes and several pathways with ties to immunotherapy response.
Bio-Techne Nabs CE Mark for HPV Head and Neck Cancer Test, Completes Namocell Acquisition
The RNAscope ISH Probe High Risk HPV test detects E6/E7 mRNA and is intended to help inform treatment selection in oropharyngeal squamous cell carcinoma patients.